Navigation Links
Halozyme Reports Second Quarter 2012 Financial Results
Date:8/6/2012

  • Revenues for the second quarter of 2012 were $7.8 million, compared to $23.2 million for the second quarter of 2011. Revenues in the second quarter of 2012 primarily consisted of $2 million in annual exclusivity fees and $4.4 million in research and development reimbursements from partners.
  • Research and development expenses for the second quarter of 2012 were $16.1 million, compared with $15.3 million for the second quarter of 2011, primarily due to an increase in compensation costs and manufacturing activities, partially offset by a decrease in clinical trial activities. 
  • Selling, general and administrative (SG&A) expenses for the second quarter of 2012 were $5.6 million, compared to $4.6 million for the second quarter of 2011. The increase for SG&A was due to higher compensation costs during the quarter. 
  • Cash and cash equivalents were $102.0 million as of June 30, 2012, compared with $79.1 million as of June 30, 2011. Net cash used in the second quarter of 2012 was approximately $14.6 million.
  • 2012 cash burn guidance remains unchanged at $55-$60 million.
  •  

    Conference Call
    The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 398418.

    About Halozyme
    Halozyme Therapeutics is a biopharmaceutical compa
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    2. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    4. Halozyme Reports First Quarter 2012 Financial Results
    5. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    6. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2012
    7. Press Ganey Releases Enhanced Improvement Portal with Customized Performance Reports
    8. Isis Reports Financial Results And Highlights For Second Quarter 2012
    9. Champions Oncology Reports Resignation Of Director
    10. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
    11. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... , August 29, 2014 ... Oil Market by Extraction type (SFE, Cold Pressed, ... Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - ... MarketsandMarkets, defines and segments the Amaranth Seed Oil ... market size in terms of value. The Amaranth ...
    (Date:8/29/2014)... 29, 2014   Vittamed Corporation , a neurodiagnostics medical ... today that T. (Teo) Forcht Dagi , MD, DmedSc, ... of Directors. " Teo Forcht Dagi ... medical innovation and venture capital," said Remis Bistras , ... add his clinical, strategic, and entrepreneurial expertise to our Board." ...
    (Date:8/29/2014)... PITTSBURGH , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage ... at the Australian and New Zealand Forensic Science ... Forensic Sciences in Adelaide, Australia ... discussion concerning the advancements that hyperspectral imaging can ... Jeffrey Beckstead , Director of Product Development ...
    Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
    ... (NASDAQ: IPHS ), the leading North American ... pharmaceutical, oral care and industrial end markets, today announced ... completed the acquisition of Kelatron Corporation. Kelatron ... of bioactive mineral nutrients. For over 30 years, the ...
    ... Filtrona Porous Technologies, a developer and manufacturer of custom ... will introduce a new range of hydrophilic, polyurethane foams ... COMPAMED trade fair in Dusseldorf, Germany from 16 to ... New innovations to be featured at ...
    Cached Medicine Technology:Innophos Holdings, Inc. Announces Acquisition of Kelatron Corporation 2Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair 2
    (Date:9/1/2014)... 01, 2014 An operating theatre or ... for performing surgical operations. An operating room comprises a ... booms, operating room lights, imaging displays as well as ... by Transparency Market Research, a U.S.-based market research firm, ... USD 4.5 billion by 2019. , According to ...
    (Date:9/1/2014)... "Women struggle with weight gain typically associated to ... early as 15, if not earlier. Women therefore ... downs of hormone related weight gain. The battle ... to rage against the hidden and ever-present hormones which ... begin to face menopause and related changes, these hormonal ...
    (Date:9/1/2014)... By Dennis Thompson ... -- An experimental Ebola drug previously given to two American ... the deadly virus in laboratory tests, researchers report. The ... it, even if they didn,t get the medication until five ... cases of Ebola who were days or even hours away ...
    (Date:9/1/2014)... atrial fibrillation (AF) doubles the risk of stroke compared ... 6 000 patients presented at ESC Congress today by ... a simple clinical assessment of the type of AF ... Ischaemic stroke is the second cause of death in ... many more disabled patients each year. Annual direct health ...
    (Date:9/1/2014)... (PRWEB) September 01, 2014 The National ... to announce that Dawn Bazarko, DNP, MPH, RN, and ... of the American Academy of Nursing. They will be ... RN-BC, CCM, FACHE, whose induction we reported last May. ... 18, 2014, during the 2014 American Academy of Nursing ...
    Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4
    ... go indoors, , , SATURDAY, July 12 (HealthDay News) -- Summer ... so it is also the time for them to be ... is, ,When thunder roars, go indoors," Mary Ann Cooper, director ... Illinois at Chicago, said in a prepared statement. "Decisions about ...
    ... Emageon Inc.,(Nasdaq: EMAG ), a leader ... networks and imaging facilities,announced today that the Strategic ... Jefferies and Company as Lead Advisor and SunTrust,Robinson ... it evaluates all,strategic options available to the company., ...
    ... MANHATTAN BEACH, Calif., July 11 A,democratic process involving ... July 14 with hearings to determine the best way ... have the greatest strength,to win for their families and ... step in a thorough, open, and democratic,discussion to make ...
    ... $500 million in cuts, WASHINGTON, July 11 ... and pay more out of pocket,for health care, while ... legislation approved this week by the U.S. Congress., ... from the,Medicare Advantage program over a five-year period, including ...
    ... Texas, July 11 Abuelo,s restaurants today,released the ... been linked to consumption of certain raw jalapeno ... recommendation of the Centers for Disease Control (CDC),Abuelo,s ... our recipes and,plate presentations at this time. We ...
    ... In New York, the majority of Medicaid LTC Funds ... A new report by AARP,s,Public Policy Institute finds mixed ... long-term care (LTC) options under Medicaid.,According to the report, ... Medicaid LTC dollars for older people providing home and ...
    Cached Medicine News:Health News:Summer Is Peak Time for Lightning Strikes 2Health News:Florida Seniors' Medicare Advantage Benefits at Risk 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 3
    ... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
    ... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
    ... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
    ... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
    Medicine Products: